Format

Send to

Choose Destination
See comment in PubMed Commons below
Acta Neuropathol Commun. 2013 Aug 9;1:49. doi: 10.1186/2051-5960-1-49.

Reducing TDP-43 aggregation does not prevent its cytotoxicity.

Author information

1
Brain Research Center, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC V6T2B5, Canada. cynader@brain.ubc.ca.

Abstract

BACKGROUND:

TAR DNA-binding protein 43 (TDP-43) is a protein that is involved in the pathology of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD). In patients with these neurodegenerative diseases, TDP-43 does not remain in its normal nuclear location, but instead forms insoluble aggregates in both the nucleus and cytoplasm of affected neurons.

RESULTS:

We used high density peptide array analysis to identify regions in TDP-43 that are bound by TDP-43 itself and designed candidate peptides that might be able to reduce TDP-43 aggregation. We found that two of the synthetic peptides identified with this approach could effectively inhibit the formation of TDP-43 protein aggregates in a concentration-dependent manner in HeLa cells in which a mutated human TDP-43 gene was overexpressed. However, despite reducing aggregation, these peptides did not reduce or prevent cell death. Similar results were observed in HeLa cells treated with arsenite. Again we found reduced aggregation, in this case of wild type TDP-43, but no difference in cell death.

CONCLUSIONS:

Our results suggest that TDP-43 aggregation is associated with the cell death process rather than being a direct cause.

PMID:
24252504
PMCID:
PMC3893365
DOI:
10.1186/2051-5960-1-49
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center